XML 21 R11.htm IDEA: XBRL DOCUMENT
v3.21.2

Financial Instruments | 9 Months Ended
--- | ---
Sep. 30, 2021
Financial Instruments [Abstract] |
Financial Instruments | 5. Financial Instruments The following is a summary of our financial instruments measured at fair value on a recurring basis (in thousands):
September 30, 2021 | Level 1 |  | Level 2 |  | Level 3 |  | Total
Cash equivalents: |  |  |  |  |  |  |  |  |  |  |
Money market funds | $ | 10,012 |  | $ | -- |  | $ | -- |  | $ | 10,012
Restricted securities: |  |  |  |  |  |  |  |  |  |  |
Money market funds |  | 538 |  |  | -- |  |  | -- |  |  | 538
Endospan loan |  | -- |  |  | -- |  |  | 409 |  |  | 409
Total assets | $ | 10,550 |  | $ | -- |  | $ | 409 |  | $ | 10,959
Current liabilities: |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  | -- |  |  | -- |  |  | (17,600) |  |  | (17,600)
Long-term liabilities: |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  | -- |  |  | -- |  |  | (47,300) |  |  | (47,300)
Total liabilities | $ | -- |  | $ | -- |  | $ | (64,900) |  | $ | (64,900)
December 31, 2020 | Level 1 |  | Level 2 |  | Level 3 |  | Total
Cash equivalents: |  |  |  |  |  |  |  |  |  |  |
Money market funds | $ | 11,484 |  | $ | -- |  | $ | -- |  | $ | 11,484
Restricted securities: |  |  |  |  |  |  |  |  |  |  |
Money market funds |  | 546 |  |  | -- |  |  | -- |  |  | 546
Endospan loan |  | -- |  |  | -- |  |  | 409 |  |  | 409
Total assets | $ | 12,030 |  | $ | -- |  | $ | 409 |  | $ | 12,439
Current liabilities: |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  | -- |  |  | -- |  |  | (16,430) |  |  | (16,430)
Long-term liabilities: |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  | -- |  |  | -- |  |  | (43,500) |  |  | (43,500)
Total liabilities | $ | -- |  | $ | -- |  | $ | (59,930) |  | $ | (59,930)
We used prices quoted from our investment advisors to determine the Level 1 valuation of our investments in money market funds. We recorded the Endospan Loan, classified as Level 3, as a result of an agreement with Endospan in September 2019. The fair value of the contingent consideration component of the Ascyrus acquisition was updated using Level 3 inputs. See Note 3 and Note 4 for further discussion of the Ascyrus acquisition and the Endospan Loan, respectively. Changes in fair value of Level 3 assets and liabilities are listed in the tables below (in thousands):
| Endospan Loan |  | Contingent Consideration
Balance as of December 31, 2020 | $ | 409 |  | $ | (59,930)
Change in valuation |  | -- |  |  | (4,970)
Balance as of September 30, 2021 | $ | 409 |  | $ | (64,900)

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration